After years of groundbreaking research and millions in development costs, the future of a revolutionary gene therapy can come down to something surprisingly mundane: filling a vial. This is the paradox of viral vector manufacturing – the most sophisticated medical breakthroughs of our time depend on getting the final step exactly right, where even microscopic contamination or a slight variation in concentration can render a life-changing treatment useless.
Fill/finish operations for virus- and viral-vector-based drugs and vaccines represent this critical last mile in bringing advanced therapies to patients. The challenge is maintaining absolute sterility while preventing any exposure to operators and the environment – all while working with products so sensitive that traditional sterilization methods would destroy them entirely. This forces manufacturers into aseptic processing, where precision isn’t just important – it’s everything.
Why Partnerships Drive Success
The fundamental constraint with viral vectors is that they can’t survive the harsh sterilization conditions that work for traditional pharmaceuticals. This means manufacturers must use aseptic processing where every step maintains sterility without using terminal sterilization as a safety net. Different viral vectors behave differently under processing conditions, requiring customized approaches that balance sterility assurance with maintaining product integrity.
For most organizations, especially those in early-stage development, partnering with experienced CDMOs provides immediate access to proven capabilities without the capital investment and operational complexity of building specialized in-house capacity. The learning curve for mastering aseptic fill/finish can take years – CDMOs with established track records have already navigated these challenges and refined their processes through experience with multiple products and regulatory interactions.
What True Expertise Delivers
Leading CDMOs demonstrate their capabilities through metrics that matter: exceptionally low reject rates, minimal product losses during filling, and the ability to handle diverse product types while maintaining stringent quality standards. True expertise extends beyond regulatory compliance to operational excellence that consistently delivers measurable results.
The most capable partners offer services that complement filling operations, including formulation development, sterile filtration and aseptic transfer, vial labeling, complete release testing, and thorough visual inspection. This integrated approach eliminates handoffs between multiple vendors, reducing risk while ensuring consistent quality throughout the entire process.
Modern operations must accommodate impressive product diversity – from AAVs and vaccines to oncolytic viruses across various container configurations and batch sizes. Given the high value of these products, strategies that minimize product losses directly impact manufacturing economics. When a single batch represents months of upstream processing and significant investment, every milliliter matters.
The Future is Automated
Leading CDMOs distinguish themselves through deployment of state-of-the-art automation and quality-control technologies. Fully automated aseptic filling lines minimize cross-contamination risks and increase sterility assurance while simultaneously reducing product losses – addressing two of the most critical challenges in viral vector fill/finish operations. Automation eliminates variables associated with manual operations, providing more consistent results and reducing potential for human error.
Ascend’s Proven Fill/Finish Excellence
ABL, Inc. became part of Ascend in 2024, bringing a distinguished 60-year track record of supplying scalable CDMO services to developers of viral-vector and virus-based therapies through advanced technologies. This partnership combines proven expertise with innovative approaches to meet the evolving needs of the advanced therapy industry.
At the Rockville, Maryland location, fully automated aseptic filling line onsite minimize cross-contamination and increase sterility assurance while minimizing product losses for programs up to Phase 2. This service, which incorporates one hundred percent in-process weight checks, translates directly into industry-low reject rates that reflect the precision and reliability clients expect from their manufacturing partners.
The facility offers comprehensive capabilities with pre-qualified CZ and glass vials in multiple configurations for fill volumes ranging from 0.5mL up to 9.7mL for AAVs, vaccines, oncolytic viruses, and other liquid formulations, with flexibility to accommodate larger custom requirements. Operations can be performed up to BSL2 safety levels for any customer type, from academic laboratories to multinational companies, with batch sizes ranging from 200 to 3,000 vials.
The filling process has been specifically optimized for low hold-up volume and minimal line loss – critical when working with high-value viral vector products. Complementing these capabilities, the facility provides formulation development, sterile filtration and aseptic transfer, vial labeling, complete release testing, and 100% visual inspection, creating an integrated solution that maintains quality throughout the entire process.
In Alachua, Florida, this legacy continues with installation of cutting-edge cGMP fill/finish capacity. A customized GENiSYS® C filling machine from AST, scheduled for 2025 installation, will strengthen Ascend’s specialized offering with access to fourth-generation fill/finish technology.
The GENiSYS C delivers enterprise-level capabilities in a flexible format, featuring 60-minute cycle times and automated, multi-format processing for vials, syringes, and cartridges on a compact, no-touch production line. Fully automatic operations with pharmaceutical-grade aluminum capping minimize operator interaction, reducing contamination risks while maintaining the highest quality standards.
The filler installed at the Alachua facility will be seamlessly integrated into an ergonomically designed fill/finish isolator designed in conjunction with Germfree that includes a novel decontamination technology, both of which are controlled using the AST View intuitive human-machine Interface as a single point of information and control. The isolator barrier technology eliminates common points of friction, while the 7000ei bio-decontamination system from CURIS leverages federally approved low-concentration 7% hydrogen peroxide technology for the quickest cycle times with superior material compatibility and virtually no outgassing.
Precision Where It Matters Most
Viral vector manufacturing demands partners who understand both the science and the systems required for success. As the advanced therapy industry evolves, success belongs to those who recognize the strategic value of partnering with CDMOs that combine deep technical expertise, proven operational excellence, and ongoing investment in next-generation technologies.
For developers of viral vector therapies and vaccines, the choice of fill/finish partner represents more than a manufacturing decision – it’s a strategic choice that can accelerate development timelines, reduce risks, and ultimately determine whether groundbreaking science successfully reaches the patients who need it most.
Click here to learn more about our Fill/Finish services
